Australia markets close in 28 minutes

Alphamab Oncology (3NK.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.2760+0.0020 (+0.73%)
At close: 08:04AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
218,774
218,774
166,845
146,021
0
Cost of revenue
55,237
55,237
44,207
3,028
0
Gross profit
163,537
163,537
122,638
142,993
0
Operating expenses
Research development
407,524
407,524
468,238
481,361
331,241
Selling general and administrative
79,338
79,338
86,771
77,251
78,208
Total operating expenses
469,087
469,087
531,114
544,980
364,551
Operating income or loss
-305,550
-305,550
-408,476
-401,987
-364,551
Interest expense
12,179
12,179
14,206
13,182
11,826
Income before tax
-210,593
-210,593
-325,722
-412,417
-427,766
Income tax expense
0
0
0
0
0
Income from continuing operations
-210,593
-210,593
-325,722
-412,417
-427,766
Net income
-210,593
-210,593
-325,722
-412,417
-427,766
Net income available to common shareholders
-210,593
-210,593
-325,722
-412,417
-427,766
Basic EPS
-0.23
-0.22
-0.35
-0.44
-0.46
Diluted EPS
-0.23
-0.22
-0.35
-0.44
-0.46
Basic average shares
947,029
959,899
936,502
935,486
929,749
Diluted average shares
947,029
959,899
936,502
935,486
929,749